Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | PRKACA | P17612 | 2/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280594 | 0.87 | PLG (0.39) | DGAT1CDK5DYRK1ARAB9ANPC1 | |
| SCHEMBL30209249 | 0.85 | RXFP1 (0.41) | CDK5PDGFRATYRO3DYRK1ARAB9A | |
| SCHEMBL260308 | 0.85 | RXFP1 (0.41) | CDK5PDGFRATYRO3DYRK1ARAB9A | |
| SCHEMBL24898414 | 0.80 | BCKDK (0.40) | CDK5DYRK1APARP1PIM1PRKACA | |
| SCHEMBL12211160 | 0.80 | BCL2L1 (0.40) | DYRK1ARAB9ANPC1PARP1ICAM1 | |
| SCHEMBL1096910 | 0.80 | ELANE (0.46) | DYRK1ARAB9ANPC1CYP1A2CYP3A4 | |
| SCHEMBL14352536 | 0.76 | EPAS1 (0.37) | CDK5PDGFRATYRO3DYRK1ARAB9A | |
| SCHEMBL492447 | 0.76 | GABRA1 (0.39) | CDK5PDGFRATYRO3DYRK1ARAB9A | |
| SCHEMBL492013 | 0.76 | ELANE (0.49) | RAB9ANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4774968 | 0.76 | SMN1; SMN2 (0.45) | DYRK1ARAB9ANPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728199-B1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2025-05-14 | — | — | EP | disclosed |
| CN-111491925-B | Pesticidal compounds | 巴斯夫欧洲公司 | 2023-12-29 | — | — | CN | disclosed |
| US-11512054-B2 | Pesticidal compounds | BASF SE (DE) | 2022-11-29 | — | — | US | disclosed |
| US-20210070713-A1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2021-03-11 | — | — | US | disclosed |
| EP-3728199-A1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111491925-A | Pesticidal compounds | 巴斯夫欧洲公司 | 2020-08-04 | — | — | CN | disclosed |
| WO-2017128896-A1 | FXR AGONIST AND PREPARATION METHOD AND USE THEREOF | 江苏豪森药业集团有限公司 | 2017-08-03 | — | — | WO | disclosed |
| EP-1991531-A1 | CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070713-A1 | PESTICIDAL COMPOUNDS | CAT, NIT2, PNMT | DGAT1 2883/4885CDK5 1349/4885PDGFRA 4515/4885 |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | DGAT1 1019/4885CDK5 433/4885PDGFRA 3496/4885 |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | DGAT1 1016/4885CDK5 548/4885PDGFRA 3587/4885 |
| US-11512054-B2 | Pesticidal compounds | CAT, NIT2, PNMT | DGAT1 2883/4885CDK5 1349/4885PDGFRA 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.